A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
pixel
J. Scott Wolchko net worth and biography

J. Wolchko Biography and Net Worth

Mr. Wolchko is the President & Chief Executive Officer at Fate Therapeutics and is responsible for the company’s finance, administration and operations. Mr. Wolchko began his career as an investment banker with Morgan Stanley & Co., where he served for six years in the firm’s New York City and Menlo Park, California offices. As a member of Morgan Stanley’s Investment Banking Health Care Group, he assisted emerging growth companies in the health care technology sector complete capital-raising and M&A transactions. Prior to joining Fate Therapeutics, Mr. Wolchko served as the Chief Financial Officer of Bocada, Inc., where he oversaw all corporate service-related operations, and previously led Corporate Development at drugstore.com, where he was responsible for sourcing, evaluating and executing financial and business development opportunities. Mr. Wolchko holds an M.S. in biochemical engineering from the University of Virginia, and a B.S. in biomedical engineering from the University of Vermont.

What is J. Scott Wolchko's net worth?

The estimated net worth of J. Scott Wolchko is at least $9.77 million as of July 21st, 2022. Mr. Wolchko owns 431,546 shares of Fate Therapeutics stock worth more than $9,774,517 as of October 3rd. This net worth approximation does not reflect any other investments that Mr. Wolchko may own. Additionally, Mr. Wolchko receives an annual salary of $976,000.00 as CEO at Fate Therapeutics. Learn More about J. Scott Wolchko's net worth.

How old is J. Scott Wolchko?

Mr. Wolchko is currently 52 years old. There are 4 older executives and no younger executives at Fate Therapeutics. Learn More on J. Scott Wolchko's age.

What is J. Scott Wolchko's salary?

As the CEO of Fate Therapeutics, Inc., Mr. Wolchko earns $976,000.00 per year. Learn More on J. Scott Wolchko's salary.

How do I contact J. Scott Wolchko?

The corporate mailing address for Mr. Wolchko and other Fate Therapeutics executives is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. Fate Therapeutics can also be reached via phone at (858) 875-1800 and via email at [email protected] Learn More on J. Scott Wolchko's contact information.

Has J. Scott Wolchko been buying or selling shares of Fate Therapeutics?

J. Scott Wolchko has not been actively trading shares of Fate Therapeutics during the last quarter. Most recently, J Scott Wolchko sold 30,000 shares of the business's stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $32.88, for a transaction totalling $986,400.00. Following the completion of the sale, the chief executive officer now directly owns 431,546 shares of the company's stock, valued at $14,189,232.48. Learn More on J. Scott Wolchko's trading history.

Who are Fate Therapeutics' active insiders?

Fate Therapeutics' insider roster includes Yu-Waye Chu (VP), Edward Dulac, III (CFO), John Mendlein (Director), Louis Petrillo (Insider), Mark Plavsic (Insider), Cindy Tahl (General Counsel), Bahram Valamehr (Insider), and J. Wolchko (CEO). Learn More on Fate Therapeutics' active insiders.

Are insiders buying or selling shares of Fate Therapeutics?

In the last year, insiders at the biopharmaceutical company sold shares 21 times. They sold a total of 330,543 shares worth more than $14,201,241.14. The most recent insider tranaction occured on August, 18th when CFO Edward J Dulac III sold 5,135 shares worth more than $153,074.35. Insiders at Fate Therapeutics own 17.3 % of the company. Learn More about insider trades at Fate Therapeutics.

Information on this page was last updated on 8/18/2022.

J. Scott Wolchko Insider Trading History at Fate Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/21/2022Sell30,000$32.88$986,400.00431,546View SEC Filing Icon  
4/21/2022Sell30,000$35.00$1,050,000.00431,546View SEC Filing Icon  
1/20/2022Sell30,000$40.21$1,206,300.00View SEC Filing Icon  
1/10/2022Sell34,156$46.86$1,600,550.16View SEC Filing Icon  
11/18/2021Sell20,000$54.27$1,085,400.00View SEC Filing Icon  
10/21/2021Sell30,000$60.22$1,806,600.00View SEC Filing Icon  
8/19/2021Sell20,000$88.01$1,760,200.00View SEC Filing Icon  
7/22/2021Sell30,000$86.05$2,581,500.00View SEC Filing Icon  
4/23/2021Sell30,000$85.24$2,557,200.00423,793View SEC Filing Icon  
1/21/2021Sell30,000$103.05$3,091,500.00393,793View SEC Filing Icon  
1/11/2021Sell69,407$116.33$8,074,116.31393,065View SEC Filing Icon  
1/8/2021Sell60,820$117.10$7,122,022.00393,065View SEC Filing Icon  
11/13/2020Sell60,000$51.87$3,112,200.00
1/30/2020Sell25,000$25.45$636,250.00444,969View SEC Filing Icon  
12/20/2019Sell25,000$20.17$504,250.00378,969View SEC Filing Icon  
10/15/2019Sell21,017$14.44$303,485.48View SEC Filing Icon  
5/16/2019Sell14,335$19.37$277,668.95389,216View SEC Filing Icon  
4/17/2019Sell8,541$16.17$138,107.97375,973View SEC Filing Icon  
3/21/2019Sell20,000$17.61$352,200.00View SEC Filing Icon  
4/1/2014Sell20,000$9.64$192,800.00View SEC Filing Icon  
See Full Table

J. Scott Wolchko Buying and Selling Activity at Fate Therapeutics

This chart shows J Scott Wolchko's buying and selling at Fate Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Fate Therapeutics Company Overview

Fate Therapeutics logo
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $22.65
Low: $22.03
High: $23.11

50 Day Range

MA: $28.38
Low: $21.04
High: $36.06

2 Week Range

Now: $22.65
Low: $17.10
High: $66.56

Volume

82,172 shs

Average Volume

1,447,065 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.69
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.
pixel